Private EquityScreenerRefer

MARKET INSIGHTS

  • EventsNEWPrivate market milestones
  • NewsPrecize daily pulse
  • BlogsIn-depth articles and opinions

GUIDES

Explore Now
  • Unlisted SharesStep-by-step · KYC
  • BuyingStep-by-step · KYC
  • SellingExit in 24 - 48 hours
  • Pre-IPOReturns · risks · case studies
  • Tax GuideBudget 2026 changes
  1. Home
  2. Unlisted share news
  3. PharmEasy investor cuts value of its stake drastically, implying new va…

PharmEasy investor cuts value of its stake drastically, implying new valuation of $456M

26 Dec 2024

Add as preferred source
Key Takeaways

PharmEasy’s valuation has dropped by 92%, reflecting ongoing financial struggles despite raising over $1 billion and securing fresh capital.

PharmEasy’s valuation has dropped by 92%, reflecting ongoing financial struggles despite raising over $1 billion and securing fresh capital.

pharmeasy unlisted shares

API Holdings (Pharmeasy)

-8.09%

Expert Analysis

PharmEasy Investor Slashes Stake Value, New Valuation Drops to $456M.

Expert Analysis:

  • New Valuation: PharmEasy is now valued at $456 million, based on Janus Henderson’s filing, which values its 12.9 million shares at $766,043.

  • Original Investment and Valuation Drop: Janus Henderson’s Global Research Fund originally spent $9.4 million to acquire the shares, with the current valuation down 92% from PharmEasy’s all-time high of $5.6 billion.

  • Fresh Capital and IPO Plans: Despite raising over $200 million in fresh capital earlier this year, the valuation remains low as PharmEasy prepares to file for an initial public offering next year.

  • Rights Issue and Capital Raised: In 2023, PharmEasy raised $417 million through a rights issue amidst a funding crunch, with $216 million secured by April 2024.

  • Backers and Market Position: PharmEasy, backed by Prosus, Temasek, TPG, and B Capital, operates one of India’s largest online pharmacies.

  • Thyrocare Acquisition: PharmEasy's current valuation is much lower than the $600 million it paid to acquire Thyrocare in 2021. 

  • Financial Challenges: After deferring an $843 million IPO in 2021, PharmEasy struggled with debt, including a $300 million loan from Goldman Sachs, and difficulties raising new equity in a tough market.

Publisher:Tech Crunch